Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
Novartis
Novartis
Sanofi
Janssen Research & Development, LLC
Amgen
Janssen Research & Development, LLC
Hoffmann-La Roche
Bio-Path Holdings, Inc.
Pfizer
Merck Sharp & Dohme LLC
Texas Oncology Cancer Center